Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Long-term Favorable Outcomes of Radiofrequency Ablation for Hepatocellular Carcinoma as an Initial Treatment: A Single-center Experience Over a 10-Year Period

MASAYO TSUKAMOTO, YO-ICHI YAMASHITA, KATSUNORI IMAI, NAOKI UMEZAKI, TAKANOBU YAMAO, TAKAYOSHI KAIDA, KOSUKE MIMA, SHIGEKI NAKAGAWA, DAISUKE HASHIMOTO, AKIRA CHIKAMOTO, TAKATOSHI ISHIKO and HIDEO BABA
Anticancer Research February 2018, 38 (2) 1047-1052;
MASAYO TSUKAMOTO
Department of Gastroenterological Surgery, Kumamoto University Graduate School of Life Sciences, Kumamoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YO-ICHI YAMASHITA
Department of Gastroenterological Surgery, Kumamoto University Graduate School of Life Sciences, Kumamoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATSUNORI IMAI
Department of Gastroenterological Surgery, Kumamoto University Graduate School of Life Sciences, Kumamoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NAOKI UMEZAKI
Department of Gastroenterological Surgery, Kumamoto University Graduate School of Life Sciences, Kumamoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKANOBU YAMAO
Department of Gastroenterological Surgery, Kumamoto University Graduate School of Life Sciences, Kumamoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAYOSHI KAIDA
Department of Gastroenterological Surgery, Kumamoto University Graduate School of Life Sciences, Kumamoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOSUKE MIMA
Department of Gastroenterological Surgery, Kumamoto University Graduate School of Life Sciences, Kumamoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHIGEKI NAKAGAWA
Department of Gastroenterological Surgery, Kumamoto University Graduate School of Life Sciences, Kumamoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAISUKE HASHIMOTO
Department of Gastroenterological Surgery, Kumamoto University Graduate School of Life Sciences, Kumamoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AKIRA CHIKAMOTO
Department of Gastroenterological Surgery, Kumamoto University Graduate School of Life Sciences, Kumamoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKATOSHI ISHIKO
Department of Gastroenterological Surgery, Kumamoto University Graduate School of Life Sciences, Kumamoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDEO BABA
Department of Gastroenterological Surgery, Kumamoto University Graduate School of Life Sciences, Kumamoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hdobaba@kumamoto-u.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Radiofrequency ablation (RFA) is an alternative to hepatic resection and one of the major therapeutic options for hepatocellular carcinoma (HCC). Here, we investigated the long-term outcomes of RFA as an initial treatment for HCC. Patients and Methods: From January 2000 to December 2014, we treated 1,043 patients with RFA for HCC at the Kumamoto University Hospital; 327 of these patients (31.4%) were treated for primary HCC. After exclusion of 75 patients who underwent combined therapy, data for 252 patients were examined. We retrospectively analyzed the long-term outcomes of RFA and identified factors of poor prognosis. Results: The median platelet count, prothrombin activity and indocyanine green retention rate at 15 min were 9.1×104/μl, 83% and 26%, respectively. The 5-year overall survival (OS) rate was 69% and the median survival time was 7.0 years. The 5-year recurrence-free survival (RFS) rate was 17%, and the median RFS was 2.0 years. A multivariate analysis revealed that age >80 years [hazard ratio (HR)=7.76, p=0.011], tumor diameter >2 cm (HR=1.68, p=0.047) and multiple tumors (HR=1.87, p=0.014) were independent prognostic factors for poor OS. For RFS, des-γ-carboxy prothrombin (DCP) ≥40 mAU/ml (HR=1.47, p=0.038) and multiple tumors (HR=1.63, p=0.0056) were independent prognostic factors. Local recurrence at the ablated site occurred in 33/252 patients (13%), and in 33/372 tumors (8.9%). Conclusion: Although our cohort included patients with relatively worse liver function, a favorable 5-year survival rate 69% was obtained by RFA. DCP ≥40 mAU/ml and multiple HCCs contribute to a higher risk of recurrence. Patients with these factors should therefore be followed-up intensively.

  • Radiofrequency ablation
  • hepatocellular carcinoma
  • long-term outcomes

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world (1). Many treatments are now available for HCC, including hepatic resection, local ablation therapy, transcatheter hepatic arterial chemoembolization (TACE), and transplantation (2). Local ablation such as radiofrequency ablation (RFA), microwave coagulation and percutaneous ethanol injection play important roles in the management of HCC (3). Hepatic resection or RFA is recommended for HCCs with a diameter of ≤3 cm in patients with good liver functional reserve, according to the guidelines established by the American Association for the Study of the Liver Disease (4), the European Association for the Study of the Liver (5) and Japanese evidence-based guidelines (6, 7)

RFA is becoming an alternative therapy for small HCC tumors (≤3 cm) because it is efficient and has an extremely low associated mortality rate, and it is much less invasive than hepatic resection (8, 9). The 5-year overall survival (OS) rate after percutaneous RFA of small HCCs is reported to be comparable to that of hepatic resection (7, 10-12). However, relatively high local recurrence rates of HCC following RFA have been reported, with 1-year local recurrence rates ranging from 9.7% to 15.0% and 3-year local recurrence rates ranging from 19% to 27% (13-16). It was also reported that 12.5% of a series of patients with HCC showed biopsy-proven needle-track seeding 4-18 months after RFA, and intrahepatic dissemination after RFA could be a serious problem (17-19). It is thus important to evaluate long-term outcomes and identify risk factors for recurrence after RFA for HCC.

Here we retrospectively examined the long-term outcomes after RFA as initial treatment for patients with HCC with relatively unlimited tumor size and liver function, and identified factors of poor prognosis in the patients.

Patients and Methods

Patients. From January 2000 to December 2014, we treated 1043 patients with RFA for HCC at Kumamoto university hospital. Of these patients, 327 (31.4%) were treated for primary HCC. Seventy-five patients (22.9%) were excluded from the study because they had undergone RFA combined with therapies such as hepatic resection (67 patients), microware coagulation (one patient) and percutaneous ethanol injection (eight patients). Thus, a final total of 252 patients were examined. The median follow-up time of this patient series was 41 months.

RFA procedures. When a patient's tumor was not close to the liver surface and was detected by percutaneous ultrasonography, percutaneous ultrasonography-guided RFA was selected. When the tumor was located on the liver surface or was undetectable by percutaneous ultrasonography, laparoscopic RFA or RFA with laparotomy was selected (20). When the tumor was located near the hepatic dome and was undetectable by percutaneous ultrasonography, thoracoscopic RFA or RFA with thoracotomy was selected (20). When tumors were multiple and located on the liver surface or deeper, percutaneous and laparoscopic or thoracoscopic RFA were combined.

For tumor ablation, an electrode with a 2- to 3-cm exposed tip (Radionics, Burlington, MA, USA) connected to a 500-kHz RF Generator (Radionics) was used. A tip temperature of 10-20°C was maintained by chilled saline solution infusion via a peristaltic pump. After electrode insertion into the lesion, we gradually increased the power to 60 W in a 2-cm-long needle or 80 W in a 3-cm-long needle at the rate of 20 W/min. After ablation exposure, we stopped the pump and measured the temperature of the needle tip. To achieve an accurate and wide tumor margin, we ablated not only the tumor nodule, but also the area surrounding the tumor, especially if the target nodule was >2 cm in diameter. Enhanced computed tomography (CT) was performed 7 days after RFA to evaluate the tumor response to RFA in all patients. Complete ablation was defined as the absence of contrast enhancement within the entire tumor. The procedure was repeated if an unablated tumor remnant was suspected.

Statistical analysis. Continuous variables are expressed as means±standard deviation (SD) and were compared using Student's t-test. Categorical variables were compared using either the chi-squared test or Fisher's exact test, as appropriate. Any death that occurred in the hospital after RFA was recorded as a mortality. Grade III-V complications of Clavien-Dindo classification (21) were recorded as morbidity. The OS and RFS curves were generated by the Kaplan–Meier method and compared by the log-rank test. We subjected variables that exhibited a probability value of less than 0.05 in a univariate analysis to a multivariate analysis using the Cox proportional hazards model. All analyses were performed with JMP® Pro 9.0.2 (SAS, Cary, NC). p-Values of less than 0.05 were considered significant.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Clinical characteristics of our cohort. Data are the mean ±SD or number.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Tumor-related and surgical factors of our cohort. Data are the mean±SD or number.

Results

Patient clinicopathological characteristics. The clinical characteristics of our cohort are summarized in Table I. The median age was 68 years. The ratio of men to women was 3 to 2. The tumor-related and surgical factors of our cohort are summarized in Table II. The median tumor size was 2 (0.5-6.7) cm. The numbers of single- and multiple-HCC were 162 and 77 patients, respectively. We treated a maximum of 10 tumors at one time.

Prognostic factors related to OS and RFS. The survival curves related to OS and RFS are illustrated in Figure 1. The 5-year OS rate was 69%, and the median survival time was 7.0 years. The 5-year RFS rate was 17%, and the median recurrence-free survival time was 2.0 years.

The univariate analysis revealed the following as factors of poor prognosis for OS: age >80 years, alpha-fetoprotein (AFP) ≥10 ng/ml, Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) ≥0.6%, des-γ-carboxy prothrombin (DCP) ≥40 mAU/ml, tumor diameter >2 cm and multiple tumors (Table III). The multivariate analysis revealed that age >80 years [hazard ratio (HR) =7.76, p=0.011], tumor diameter >2 cm (HR=1.68, p=0.047), and multiple tumors (HR=1.87, p=0.014) were independent factors of poor prognosis for OS (Table IV).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

(a) The overall survival (OS) after radiofrequency ablation for primary hepatocellular carcinoma. The 5-year OS was 69%. (b) The recurrence-free survival (RFS) after radiofrequency ablation for primary hepatocellular carcinoma. The 5-year RFS was 17%.

For RFS, albumin <4.1 g/dl, AFP ≥10 ng/ml, AFP-L3 ≥0.6%, DCP ≥40 mAU/ml, and multiple tumors were identified as factors of poor prognosis in the univariate analysis (Table V). The multivariate analysis showed that DCP ≥40 mAU/ml (HR=1.47, p=0.038) and multiple tumors (HR=1.63, p=0.0056) were independent factors of poor prognosis for RFS (Table VI).

Prognostic factors related to local recurrence. We defined local recurrence after RFA as tumor recurrence in or on the ablation sites. Local recurrence at the ablated site occurred in 33 patients (13%), in other words, 33 out of a total of 372 HCCs (8.9%). After recurrence, 13 patients (39%) were treated with RFA again, 13 patients (39%) with TACE, two patients (6%) with hepatic resection, one (3%) with radiotherapy, and four patients (12%) were provided only best supportive care. The univariate analysis revealed DCP ≥40 mAU/ml as the significant predictive factor for local recurrence (p=0.0039).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Univariate analysis of factors related to overall survival.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Multivariate analysis of factors related to overall survival.

Discussion

The median follow-up time in this study, 41 months, was long compared to the 10.4-38.3 months in previous studies (1, 2, 7, 22-24). Our finding of a favorable long-term outcome, i.e. 5-year OS rate of 69.0%, was obtained although our cohort included patients with relatively poor liver functional reserve such as liver damage grade B (97 patients, 42%) and C (16 patients, 7%) (1, 2, 7, 22, 24). Other studies have reported lower 5-year OS rates after RFA for HCC, i.e. 59.4-61.1% (7, 22, 24). In two of those studies, the 2- and 5-year RFS rates were reported to be 44.6-69.3% and 23.9-28.3%, respectively (7, 22). In the present study, the 2-year RFS rate was 51.5% although tumor diameter was >3 cm in 26 patients (10.3%) and 11 (4.4%) patients had more than three tumors. We believe that the 2-year RFS rate similar to those of previous studies indicates that the efficacy of RFA in the local control of HCC was good in our cohort. The relatively worse 5-year RFS rate in our cohort suggests that more patients with multi-centric recurrences were included.

The albumin value (1), tumor diameter >2 cm, multiple tumors, AFP ≥15 ng/ml, AFP-L3 >15%, DCP ≥40 mAU/ml, age, hepatitis C virus positivity and Child-Pugh score B (2, 24) have been reported as independent prognostic factors for OS in patients with HCC. Here, we identified age >80 years, tumor diameter >2 cm, and multiple tumors as independent factors of poor prognosis for OS, and DCP ≥40 mAU/ml and multiple tumors as those for RFS. We have reported that the RFS and OS rates were significantly worse after RFA than after hepatic resection in cases of HCC >2 cm, whereas there were no significant differences in patients with HCCs ≤2 cm (7). Therefore, RFA would not be a good treatment option for patients with HCCs larger than 2 cm.

We also reported that patients with a high DCP level (>100 mAU/ml) are at risk for microinvasion even for those with HCCs ≤2 cm (25). Tumor size and the value of DCP can be confirmed before the treatment decision is made, and we therefore recommend that hepatic resection, not RFA, be performed in cases of HCC larger than 2 cm and for patients with a DCP value ≥40 mAU/ml.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table V.

Univariate analysis of factors related to recurrence-free survival.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table VI.

Multivariate analysis of factors related to recurrence-free survival.

The limitations of this study include its retrospective and single-center design. We need to confirm our outcomes in more patients in multiple centers and compare our RFA outcomes to those obtained with hepatic resection and TACE. We are now registering our patients in and expecting the results of the Efficacy of Surgery vs. Radiofrequency A blation on Primary Hepatocellular Carcinoma (SURF) trial (26).

In conclusion, favorable prognosis, i.e. 69% 5-year survival rate, was obtained by RFA although our cohort included patients with poor liver function. Patients with DCP values ≥40 mAU/ml or multiple HCCs have a higher risk of recurrence, and clinicians should therefore choose RFA, hepatic resection or other treatments in a thoughtful manner and provide an intensive follow-up, especially for such patients.

Footnotes

  • Conflicts of Interest

    The Authors declare they have no conflict of interest in regard to this study.

  • Ethical approval

    All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

    Informed consent: Informed consent was obtained from all individual participants included in the study.

  • Received November 5, 2017.
  • Revision received November 22, 2017.
  • Accepted November 28, 2017.
  • Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Chen MS,
    2. Li JQ,
    3. Zheng Y,
    4. Guo RP,
    5. Liang HH,
    6. Zhang YQ,
    7. Lin XJ,
    8. Lau WY
    : A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243(3): 321-328, 2006.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Hasegawa K,
    2. Makuuchi M,
    3. Takayama T,
    4. Kokudo N,
    5. Arii S,
    6. Okazaki M,
    7. Okita K,
    8. Omata M,
    9. Kudo M,
    10. Kojiro M,
    11. Nakanuma Y,
    12. Takayasu K,
    13. Monden M,
    14. Matsuyama Y,
    15. Ikai I
    : Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: A preliminary report of the japanese Nationwide Survey. J Hepatol 49(4): 589-594, 2008.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Imai K,
    2. Beppu T,
    3. Chikamoto A,
    4. Mima K,
    5. Okabe H,
    6. Hayashi H,
    7. Nitta H,
    8. Ishiko T,
    9. Baba H
    : Salvage treatment for local recurrence of hepatocellular carcinoma after local ablation therapy. Hepatol Res 44(14): E335-345, 2014.
    OpenUrl
  4. ↵
    1. Bruix J,
    2. Sherman M
    : Management of hepatocellular carcinoma. Hepatology 42(5): 1208-1236, 2005.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Bruix J,
    2. Sherman M,
    3. Llovet JM,
    4. Beaugrand M,
    5. Lencioni R,
    6. Burroughs AK,
    7. Christensen E,
    8. Pagliaro L,
    9. Colombo M,
    10. Rodes J
    : Clinical management of hepatocellular carcinoma. Conclusions of the BARCELONA-2000 EASL conference. European association for the study of the liver. J Hepatol 35(3): 421-430, 2001.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Makuuchi M,
    2. Kokudo N,
    3. Arii S,
    4. Futagawa S,
    5. Kaneko S,
    6. Kawasaki S,
    7. Matsuyama Y,
    8. Okazaki M,
    9. Okita K,
    10. Omata M,
    11. Saida Y,
    12. Takayama T,
    13. Yamaoka Y
    : Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in japan. Hepatol Res 38(1): 37-51, 2008.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Imai K,
    2. Beppu T,
    3. Chikamoto A,
    4. Doi K,
    5. Okabe H,
    6. Hayashi H,
    7. Nitta H,
    8. Ishiko T,
    9. Takamori H,
    10. Baba H
    : Comparison between hepatic resection and radiofrequency ablation as first-line treatment for solitary small-sized hepatocellular carcinoma of 3 cm or less. Hepatol Res 43(8): 853-864, 2013.
    OpenUrlPubMed
  8. ↵
    1. Liu JG,
    2. Wang YJ,
    3. Du Z
    : Radiofrequency ablation in the treatment of small hepatocellular carcinoma: A meta analysis. World J Gastroenterol 16(27): 3450-3456, 2010.
    OpenUrlPubMed
  9. ↵
    1. Nitta H,
    2. Nakagawa S,
    3. Kaida T,
    4. Arima K,
    5. Higashi T,
    6. Taki K,
    7. Okabe H,
    8. Hayashi H,
    9. Hashimoto D,
    10. Chikamoto A,
    11. Ishiko T,
    12. Beppu T,
    13. Baba H
    : Pre-treatment double- or triple-positive tumor markers are predictive of a poor outcome for patients undergoing radiofrequency ablation for hepatocellular carcinoma. Surg Today 47(3): 375-384, 2017.
    OpenUrl
  10. ↵
    1. Cho YK,
    2. Kim JK,
    3. Kim WT,
    4. Chung JW
    : Hepatic resection versus radiofrequency ablation for very early-stage hepatocellular carcinoma: A markov model analysis. Hepatology 51(4): 1284-1290, 2010.
    OpenUrlCrossRefPubMed
    1. Molinari M,
    2. Helton S
    : Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: A markov model decision analysis. Am J Surg 198(3): 396-406, 2009.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Livraghi T,
    2. Meloni F,
    3. Di Stasi M,
    4. Rolle E,
    5. Solbiati L,
    6. Tinelli C,
    7. Rossi S
    : Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 47(1): 82-89, 2008.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Park W,
    2. Chung YH,
    3. Kim JA,
    4. Jin YJ,
    5. Lee D,
    6. Shim JH,
    7. Lee D,
    8. Kim KM,
    9. Lim YS,
    10. Lee HC,
    11. Lee YS,
    12. Kim PN,
    13. Sung KB
    : Recurrences of hepatocellular carcinoma following complete remission by transarterial chemoembolization or radiofrequency therapy: Focused on the recurrence patterns. Hepatol Res 43(12): 1304-1312, 2013.
    OpenUrl
    1. Ding J,
    2. Jing X,
    3. Liu J,
    4. Wang Y,
    5. Wang F,
    6. Wang Y,
    7. Du Z
    : Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma. Eur J Radiol 82(9): 1379-1384, 2013.
    OpenUrl
    1. Hori T,
    2. Nagata K,
    3. Hasuike S,
    4. Onaga M,
    5. Motoda M,
    6. Moriuchi A,
    7. Iwakiri H,
    8. Uto H,
    9. Kato J,
    10. Ido A,
    11. Hayashi K,
    12. Tsubouchi H
    : Risk factors for the local recurrence of hepatocellular carcinoma after a single session of percutaneous radiofrequency ablation. J Gastroenterol 38(10): 977-981, 2003.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Kono M,
    2. Inoue T,
    3. Kudo M,
    4. Chishina H,
    5. Arizumi T,
    6. Takita M,
    7. Kitai S,
    8. Yada N,
    9. Hagiwara S,
    10. Minami Y,
    11. Ueshima K,
    12. Nishida N,
    13. Murakami T
    : Radiofrequency ablation for hepatocellular carcinoma measuring 2 cm or smaller: Results and risk factors for local recurrence. Dig Dis 32(6): 670-677, 2014.
    OpenUrlPubMed
  14. ↵
    1. Masuda T,
    2. Beppu T,
    3. Ishiko T,
    4. Horino K,
    5. Baba Y,
    6. Mizumoto T,
    7. Hayashi H,
    8. Okabe H,
    9. Horlad H,
    10. Doi K,
    11. Okabe K,
    12. Takamori H,
    13. Hirota M,
    14. Iyama K,
    15. Baba H
    : Intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy. J Hepatobiliary Pancreat Surg 15(6): 589-595, 2008.
    OpenUrlCrossRefPubMed
    1. Mima K,
    2. Hayashi H,
    3. Imai K,
    4. Kuroki H,
    5. Nakagawa S,
    6. Okabe H,
    7. Chikamoto A,
    8. Watanabe M,
    9. Beppu T,
    10. Baba H
    : High CD44s expression is associated with the emt expression profile and intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy. J Hepatobiliary Pancreat Sci 20(4): 429-434, 2013.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Llovet JM,
    2. Vilana R,
    3. Bru C,
    4. Bianchi L,
    5. Salmeron JM,
    6. Boix L,
    7. Ganau S,
    8. Sala M,
    9. Pages M,
    10. Ayuso C,
    11. Sole M,
    12. Rodes J,
    13. Bruix J
    : Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 33(5): 1124-1129, 2001.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Doi K,
    2. Beppu T,
    3. Ishiko T,
    4. Chikamoto A,
    5. Hayashi H,
    6. Imai K,
    7. Nitta H,
    8. Baba Y,
    9. Masuda T,
    10. Okabe K,
    11. Kuramoto M,
    12. Kudo K,
    13. Ogata K,
    14. Ohchi T,
    15. Takamori H,
    16. Kikuchi K,
    17. Baba H
    : Endoscopic radiofrequency ablation in elderly patients with hepatocellular carcinoma. Anticancer Res 35(5): 3033-3040, 2015.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Dindo D,
    2. Demartines N,
    3. Clavien PA
    : Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2): 205-213, 2004.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Hasegawa K,
    2. Kokudo N,
    3. Makuuchi M,
    4. Izumi N,
    5. Ichida T,
    6. Kudo M,
    7. Ku Y,
    8. Sakamoto M,
    9. Nakashima O,
    10. Matsui O,
    11. Matsuyama Y
    : Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese Nationwide Survey. J Hepatol 58(4): 724-729, 2013.
    OpenUrl
    1. Tateishi R,
    2. Shiina S,
    3. Akahane M,
    4. Sato J,
    5. Kondo Y,
    6. Masuzaki R,
    7. Nakagawa H,
    8. Asaoka Y,
    9. Goto T,
    10. Otomo K,
    11. Omata M,
    12. Yoshida H,
    13. Koike K
    : Frequency, risk factors and survival associated with an intrasubsegmental recurrence after radiofrequency ablation for hepatocellular carcinoma. PLoS One 8(4): e59040, 2013.
    OpenUrl
  19. ↵
    1. Shiina S,
    2. Tateishi R,
    3. Arano T,
    4. Uchino K,
    5. Enooku K,
    6. Nakagawa H,
    7. Asaoka Y,
    8. Sato T,
    9. Masuzaki R,
    10. Kondo Y,
    11. Goto T,
    12. Yoshida H,
    13. Omata M,
    14. Koike K
    : Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 107(4): 569-577; quiz 578, 2012.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Yamashita Y,
    2. Tsuijita E,
    3. Takeishi K,
    4. Fujiwara M,
    5. Kira S,
    6. Mori M,
    7. Aishima S,
    8. Taketomi A,
    9. Shirabe K,
    10. Ishida T,
    11. Maehara Y
    : Predictors for microinvasion of small hepatocellular carcinoma </= 2 cm. Ann Surg Oncol 19(6): 2027-2034, 2012.
    OpenUrlPubMed
  21. ↵
    1. Hasegawa K,
    2. Kokudo N,
    3. Shiina S,
    4. Tateishi R,
    5. Makuuchi M
    : Surgery versus radiofrequency ablation for small hepatocellular carcinoma: Start of a randomized controlled trial (surf trial). Hepatol Res 40(8): 851-852, 2010.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 38 (2)
Anticancer Research
Vol. 38, Issue 2
February 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Long-term Favorable Outcomes of Radiofrequency Ablation for Hepatocellular Carcinoma as an Initial Treatment: A Single-center Experience Over a 10-Year Period
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 9 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Long-term Favorable Outcomes of Radiofrequency Ablation for Hepatocellular Carcinoma as an Initial Treatment: A Single-center Experience Over a 10-Year Period
MASAYO TSUKAMOTO, YO-ICHI YAMASHITA, KATSUNORI IMAI, NAOKI UMEZAKI, TAKANOBU YAMAO, TAKAYOSHI KAIDA, KOSUKE MIMA, SHIGEKI NAKAGAWA, DAISUKE HASHIMOTO, AKIRA CHIKAMOTO, TAKATOSHI ISHIKO, HIDEO BABA
Anticancer Research Feb 2018, 38 (2) 1047-1052;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Long-term Favorable Outcomes of Radiofrequency Ablation for Hepatocellular Carcinoma as an Initial Treatment: A Single-center Experience Over a 10-Year Period
MASAYO TSUKAMOTO, YO-ICHI YAMASHITA, KATSUNORI IMAI, NAOKI UMEZAKI, TAKANOBU YAMAO, TAKAYOSHI KAIDA, KOSUKE MIMA, SHIGEKI NAKAGAWA, DAISUKE HASHIMOTO, AKIRA CHIKAMOTO, TAKATOSHI ISHIKO, HIDEO BABA
Anticancer Research Feb 2018, 38 (2) 1047-1052;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Pelvic Recurrence After Curative Resection for Rectal Adenocarcinoma: Impact of Surgery on Survival
  • Glasgow Prognostic Score Predicts Survival and Recurrence Pattern in Patients With Hepatocellular Carcinoma After Hepatectomy
  • Small Bowel Lipomatosis: An Unusual Radiological Finding in Patients With Renal Cell Cancer on Pazopanib
Show more Clinical Studies

Similar Articles

Keywords

  • radiofrequency ablation
  • Hepatocellular carcinoma
  • long-term outcomes
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire